Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
Publication
, Journal Article
Califf, RM; Stump, D; Topol, EJ; Mark, DB
Published in: Am Heart J
May 1999
Duke Scholars
Published In
Am Heart J
DOI
ISSN
0002-8703
Publication Date
May 1999
Volume
137
Issue
5
Start / End Page
S90 / S93
Location
United States
Related Subject Headings
- Tissue Plasminogen Activator
- Thrombolytic Therapy
- Streptokinase
- Retrospective Studies
- North America
- Myocardial Infarction
- Humans
- Fibrinolytic Agents
- Decision Making
- Cost-Benefit Analysis
Citation
APA
Chicago
ICMJE
MLA
NLM
Califf, R. M., Stump, D., Topol, E. J., & Mark, D. B. (1999). Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. Am Heart J, 137(5), S90–S93. https://doi.org/10.1016/s0002-8703(99)70438-2
Califf, R. M., D. Stump, E. J. Topol, and D. B. Mark. “Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.” Am Heart J 137, no. 5 (May 1999): S90–93. https://doi.org/10.1016/s0002-8703(99)70438-2.
Califf RM, Stump D, Topol EJ, Mark DB. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. Am Heart J. 1999 May;137(5):S90–3.
Califf, R. M., et al. “Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.” Am Heart J, vol. 137, no. 5, May 1999, pp. S90–93. Pubmed, doi:10.1016/s0002-8703(99)70438-2.
Califf RM, Stump D, Topol EJ, Mark DB. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. Am Heart J. 1999 May;137(5):S90–S93.
Published In
Am Heart J
DOI
ISSN
0002-8703
Publication Date
May 1999
Volume
137
Issue
5
Start / End Page
S90 / S93
Location
United States
Related Subject Headings
- Tissue Plasminogen Activator
- Thrombolytic Therapy
- Streptokinase
- Retrospective Studies
- North America
- Myocardial Infarction
- Humans
- Fibrinolytic Agents
- Decision Making
- Cost-Benefit Analysis